{"entity":{"id":"wisdom-trial","kind":"trial","name":"WISDOM (Women Informed to Screen Depending on Measures of Risk)","aka":["WISDOM study","WISDOM screening trial"],"tldr":"WISDOM asks whether breast screening tailored to each woman's risk, using her genes, breast density and history, is as safe as screening everyone every year while causing fewer false alarms and biopsies.","summary":"WISDOM is a pragmatic trial across the University of California health systems and partners in the Athena Breast Health Network, led by Laura Esserman and opened in 2016. Women choose to be randomised or to pick an arm. In the personalised arm, a risk assessment that includes a panel of breast cancer genes, polygenic risk, family history and breast density sets when screening starts, how often it happens and whether MRI is added; women at the lowest risk screen every two years from 50, those at the highest risk more often and earlier. The comparison arm is annual mammography from age 40.\n\nThe primary question is whether the personalised approach is not inferior in the rate of late-stage cancers, with false positives, biopsies, and take-up of preventive drugs as secondary outcomes. The trial is the largest test of the idea that screening should be a personal prescription rather than one rule for all, and its risk model and consent tools have been adopted by other programmes.","status":"active","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT02620852","url":"https://clinicaltrials.gov/study/NCT02620852"},{"label":"WISDOM study","url":"https://www.thewisdomstudy.org"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":["mammography","germline-testing","polygenic-risk-scores"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":["screening"],"trials":[],"people":["laura-esserman"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02620852","phase":"observational","setting":"Women aged 40 to 74 without breast cancer: personalised, risk-based screening (start age, interval and imaging chosen from genetic and clinical risk) against annual mammography","sponsor":"University of California and the Athena Breast Health Network","result":"Ongoing pragmatic trial of risk-based versus annual screening.","yearReported":2016,"outcomes":[]},"route":"/trials/wisdom-trial/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"technology":[{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/"},{"id":"polygenic-risk-scores","kind":"technology","name":"Polygenic risk scores for cancer","route":"/technologies/polygenic-risk-scores/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}],"term":[{"id":"screening","kind":"term","name":"Screening","route":"/terms/screening/"}],"person":[{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/"}]}}